Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Etaracizumab

Drug Profile

Etaracizumab

Alternative Names: Abegrin; Anti-alpha-v-beta-3 humanised monoclonal antibody; Anti-αvβ3 monoclonal antibody; LM 609; MEDI-522; Vitaxin; Vitaxin II

Latest Information Update: 21 Jun 2007

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Applied Molecular Evolution; MedImmune
  • Developer Targesome
  • Class Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Antibody-dependent cell cytotoxicity; Apoptosis stimulants; Immunostimulants; Integrin alphaVbeta3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Colorectal cancer; Malignant melanoma; Prostate cancer; Psoriasis; Rheumatoid arthritis

Most Recent Events

  • 19 Jun 2007 MedImmune has been acquired by AstraZeneca
  • 09 Mar 2007 Discontinued - Phase-II for Malignant melanoma in USA (IV-infusion)
  • 09 Mar 2007 Discontinued - Phase-II for Prostate cancer in USA (IV-infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top